Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.40 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | ATF4 | P18848 | 4/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12885399 | 0.83 | PPARG (0.42) | PPARGPPARASLC6A4HTR2AKCNH2 | |
| SCHEMBL522666 | 0.83 | SOS1 (0.46) | SLC6A4HTR2AKCNH2ALDH1A1MAPT | |
| SCHEMBL177501 | 0.79 | HSP90AA1 (0.47) | PPARGPPARASLC6A4HTR2AKCNH2 | |
| SCHEMBL177743 | 0.79 | SOS1 (0.41) | SLC6A4HTR2A | |
| SCHEMBL1047926 | 0.76 | PPARG (0.41) | PPARGPPARASLC6A4HTR2AKCNH2 | |
| SCHEMBL276095 | 0.76 | CYP1A2 (0.46) | PPARGPPARASLC6A4HTR2AKCNH2 | |
| SCHEMBL29590981 | 0.76 | CYP1A2 (0.46) | PPARGPPARASLC6A4HTR2AKCNH2 | |
| SCHEMBL423469 | 0.74 | ESR1 (0.41) | CYP3A4 | |
| SCHEMBL3540409 | 0.74 | TSHR (0.48) | CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL1198940 | 0.74 | SLC6A4 (0.38) | SLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333383-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-10-30 | — | — | US | disclosed |
| EP-4514777-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2025-03-05 | — | — | EP | disclosed |
| CN-117500496-A | Pyrimidine and pyridinamine compounds and their use in the treatment of diseases | 艾匹根生物技术有限公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2023211195-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-11-02 | — | — | WO | disclosed |
| US-20220363640-A1 | ANTIVIRAL COMPOUNDS | Janssen Biopharma, Inc. (US) | 2022-11-17 | — | — | US | disclosed |
| US-20210403467-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2021-12-30 | — | — | US | disclosed |
| US-11021444-B2 | Antiviral compounds | Janssen Biopharma, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200331907-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-20190263754-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. (US) | 2019-08-29 | — | — | US | disclosed |
| EP-3415514-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| WO-2010067069-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PAIN | THE UNIVERSITY OF LIVERPOOL (GB) | 2010-06-17 | — | — | WO | disclosed |
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | PFIZER INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | EFREMOV IVAN | 2008-11-13 | — | — | US | disclosed |
| EP-1981876-A1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | Arrow Therapeutics Limited (GB) | 2008-10-22 | — | — | EP | disclosed |
| WO-2008012623-A1 | BENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008012622-A2 | AZABENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2007080401-A1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LIMITED (GB) | 2007-07-19 | — | — | WO | disclosed |
| EP-0456793-B1 | HALOPHENYL SUBSTITUTED HETEROCYCLIC DERIVATIVES | MERCK PATENT GMBH (DE) | 1996-10-23 | — | — | EP | disclosed |
| WO-1991009016-A2 | HALOPHENYL SUBSTITUTED HETEROCYCLIC DERIVATIVES | MERCK PATENT GMBH (DE) | 1991-06-27 | — | — | WO | disclosed |
| WO-1991009016-A1 | HALOPHENYL SUBSTITUTED HETEROCYCLIC DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1991-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263754-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | PPARG 2526/4885PPARA 2015/4885SLC6A4 3882/4885 |
| US-20250333383-A1 | N-OXIDE COMPOUNDS AND USE THEREOF | SCNN1B, SCN1B, SCN2B | PPARG 2152/4885PPARA 2527/4885SLC6A4 146/4885 |
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | PAICS, TMBIM6, ABCG2 | PPARG 102/4885PPARA 513/4885SLC6A4 642/4885 |
| US-11021444-B2 | Antiviral compounds | MAVS, SARS1, ZC3HAV1 | PPARG 2526/4885PPARA 2015/4885SLC6A4 3882/4885 |
| US-20220363640-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | PPARG 2526/4885PPARA 2015/4885SLC6A4 3882/4885 |
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | AZI2, PAICS, UGT2B7 | PPARG 377/4885PPARA 1667/4885SLC6A4 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.